Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acadia Healthcare Company, Inc.ACHC · Entity 4312 | Director | May 03, 2018 | May 07, 2018 |
| Aveanna Healthcare Holdings, Inc.AVAH · Entity 4246 | Director · 10% owner | April 28, 2021 | April 28, 2021 |
| KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686 | Director · 10% owner | March 06, 2025 | March 07, 2025 |
| Surgery Partners, Inc.SGRY · Entity 4534 | Director · 10% owner | August 31, 2017 | September 01, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acadia Healthcare Company, Inc.
Report date May 03, 2018 · Filed May 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,328 |
Reported balance
After 2018-05-03 transaction · row 1
1 source rowRow 1 · 2018-05-03 · Grant · Acquired 4,125 · Balance 12,328 F1: Shares will vest over a 3-year period in equal annual installments beginning May 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares will vest over a 3-year period in equal annual installments beginning May 3, 2019.
Aveanna Healthcare Holdings, Inc.
Report date April 28, 2021 · Filed April 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectSee footnotes | 81,029,675 |
Reported balance
Holding disclosure · report date 2021-04-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 81,029,675 F1: Represents shares of common stock held by Bain Capital Fund XI, L.P. ("Fund XI"), BCIP Associates IV (US), L.P. ("BCIP IV"), BCIP Associates IV-B (US), L.P. ("BCIP IV-B"), BCIP T Associates IV (US), L.P. ("BCIP T IV") and BCIP T Associates IV-B (US), L.P. ("BCIP T IV-B" and, together with Fund IX, BCIP IV, BCIP IV-B and BCP T IV, collectively, the "Bain Capital Entities"). F2: Bain Capital Investors, LLC ("BCI") is the ultimate general partner of the Fund IX and governs the investment strategy and decision-making process with respect to investments held by BCIP IV, BCIP IV-B, BCIP T IV and BCIP T IV-B. Mr. Gordon is a Managing Director of BCI. As a result of the relationships described in this footnote, Mr. Gordon may be deemed to share voting and dispositive power with respect to the shares held by the Bain Capital Entities. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock held by Bain Capital Fund XI, L.P. ("Fund XI"), BCIP Associates IV (US), L.P. ("BCIP IV"), BCIP Associates IV-B (US), L.P. ("BCIP IV-B"), BCIP T Associates IV (US), L.P. ("BCIP T IV") and BCIP T Associates IV-B (US), L.P. ("BCIP T IV-B" and, together with Fund IX, BCIP IV, BCIP IV-B and BCP T IV, collectively, the "Bain Capital Entities").
F2: Bain Capital Investors, LLC ("BCI") is the ultimate general partner of the Fund IX and governs the investment strategy and decision-making process with respect to investments held by BCIP IV, BCIP IV-B, BCIP T IV and BCIP T IV-B. Mr. Gordon is a Managing Director of BCI. As a result of the relationships described in this footnote, Mr. Gordon may be deemed to share voting and dispositive power with respect to the shares held by the Bain Capital Entities. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
KESTRA MEDICAL TECHNOLOGIES, LTD.
Report date March 06, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee footnotes | 27,019,225 |
Reported balance
Holding disclosure · report date 2025-03-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 27,019,225 F1: Consists of 7,109,944 common shares of the Issuer held directly by Bain Charger Holdings, L.P. ("Bain Charger') and 19,909,281 common shares of the Issuer held directly by West Affum Holdings, L.P. ("West Affum"). F2: The common shares of the Issuer held by West Affum are held for the benefit of the holders of West Affum common units, including Bain Charger, until the time such common shares are distributed to the holders of West Affum common units in accordance with the partnership agreement of West Affum. Bain Charger is the sole shareholder of West Affum GP Ltd., which is the general partner of West Affum. F3: Mr. Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), which is the general partner of Bain Charger. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger and West Affum. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 7,109,944 common shares of the Issuer held directly by Bain Charger Holdings, L.P. ("Bain Charger') and 19,909,281 common shares of the Issuer held directly by West Affum Holdings, L.P. ("West Affum").
F2: The common shares of the Issuer held by West Affum are held for the benefit of the holders of West Affum common units, including Bain Charger, until the time such common shares are distributed to the holders of West Affum common units in accordance with the partnership agreement of West Affum. Bain Charger is the sole shareholder of West Affum GP Ltd., which is the general partner of West Affum.
F3: Mr. Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), which is the general partner of Bain Charger. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger and West Affum. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Surgery Partners, Inc.
Report date August 31, 2017 · Filed September 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectSee footnote | 26,455,651 |
Reported balance
Holding disclosure · report date 2017-08-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 26,455,651 F1: Represents 26,445,651 shares of common stock that BCPE Seminole Holdings LP ("BCPE Holdings") purchased from H.I.G. Surgery Centers, LLC ("HIG") pursuant to the Stock Purchase Agreement, dated as of May 9, 2017, by and among Holdings, Surgery Partners, Inc. (the "Issuer"), H.I.G. Bayside Debt & LBO Fund II L.P. and HIG. F2: The securities reported in this Form 3 are held directly by BCPE Holdings. Bain Capital Investors, LLC ("BCI") is the sole member of BCPE Seminole GP LLC, which is the general partner of BCPE Holdings. The governance, investment strategy and decision-making process with respect to investments held by BCPE Holdings is directed by the Global Private Equity Board of BCI. Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BCPE Holdings. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Series A Convertible Perpetual Participating Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2017-08-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Represents 310,000 shares of 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") that BCPE Holdings acquired from the Issuer. F4: Each share of Series A Preferred Stock is convertible at any time, at the election of the holder, into the number of shares of common stock of the Issuer equal to the quotient obtained by dividing (a) the accrued value of such share of Series A Preferred Stock (initially, $1,000) plus any accrued but uncompounded dividends on such share by (b) the $19.00 conversion price, subject to certain anti-dilution adjustments in accordance with the terms set forth in the Series A Preferred Stock Certificate of Designation. Dividends accrue daily and compound quarterly on March 31, June 30, September 30 and December 31 of each year and are added to the accrued value of a share and, therefore, the number of shares of common stock into which each share of Series A Preferred Stock may be converted will increase over time. F5: The Series A Preferred Stock has no expiration date. F2: The securities reported in this Form 3 are held directly by BCPE Holdings. Bain Capital Investors, LLC ("BCI") is the sole member of BCPE Seminole GP LLC, which is the general partner of BCPE Holdings. The governance, investment strategy and decision-making process with respect to investments held by BCPE Holdings is directed by the Global Private Equity Board of BCI. Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BCPE Holdings. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 26,445,651 shares of common stock that BCPE Seminole Holdings LP ("BCPE Holdings") purchased from H.I.G. Surgery Centers, LLC ("HIG") pursuant to the Stock Purchase Agreement, dated as of May 9, 2017, by and among Holdings, Surgery Partners, Inc. (the "Issuer"), H.I.G. Bayside Debt & LBO Fund II L.P. and HIG.
F2: The securities reported in this Form 3 are held directly by BCPE Holdings. Bain Capital Investors, LLC ("BCI") is the sole member of BCPE Seminole GP LLC, which is the general partner of BCPE Holdings. The governance, investment strategy and decision-making process with respect to investments held by BCPE Holdings is directed by the Global Private Equity Board of BCI. Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BCPE Holdings. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3: Represents 310,000 shares of 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") that BCPE Holdings acquired from the Issuer.
F4: Each share of Series A Preferred Stock is convertible at any time, at the election of the holder, into the number of shares of common stock of the Issuer equal to the quotient obtained by dividing (a) the accrued value of such share of Series A Preferred Stock (initially, $1,000) plus any accrued but uncompounded dividends on such share by (b) the $19.00 conversion price, subject to certain anti-dilution adjustments in accordance with the terms set forth in the Series A Preferred Stock Certificate of Designation. Dividends accrue daily and compound quarterly on March 31, June 30, September 30 and December 31 of each year and are added to the accrued value of a share and, therefore, the number of shares of common stock into which each share of Series A Preferred Stock may be converted will increase over time.
F5: The Series A Preferred Stock has no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 3,282 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 65,679,781 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F4: Represents shares of common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-01 · Disposition to issuer · Disposed 80,189 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F4: Represents shares of common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 16:51 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090908 · ownership.xml · derivative · entry 4 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,189 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:51 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 65,679,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090908 · ownership.xml · nonDerivative · entry 3 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F4 · ownership.nature: Represents shares of common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:51 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 10,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090908 · ownership.xml · nonDerivative · entry 2 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F2 · price: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:51 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 3,282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090908 · ownership.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 17:22 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantCommon Stock | 10,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-070908 · ownership.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,743 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 16:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 5,480,052 | $22.81 | $124,999,986.12 |
DisclosureSEC source: 0000899243-23-019970 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 65,679,781 F2 · shares: On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering. F1 · ownership.nature: Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 17:09 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 13,780 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000899243-23-015226 · doc4.xml · derivative · entry 3 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,780 Underlying: Common Stock · 13,780 shares Expires 2033-06-07 F2 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 17:09 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | OtherCommon Stock | 432,627 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015226 · doc4.xml · nonDerivative · entry 2 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 60,199,729 F3 · kind: On June 7, 2023, BC Perception Holdings, LP ("BC Perception") distributed an aggregate of 432,627 shares of the Issuer's common stock (the "Distributed Shares") to certain of its limited partners in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Mr. Gordon did not have a pecuniary interest in any of the Distributed Shares. F4 · ownership.nature: Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 17:09 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantCommon Stock | 3,282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-015226 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,282 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 17:11 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 23,459 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0000899243-22-022865 · doc4.xml · derivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 Underlying: Common Stock · 23,459 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:26 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 42,950 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0000899243-21-023730 · doc4.xml · derivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,950 Underlying: Common Stock · 42,950 shares Expires 2031-06-10 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 17:51 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 332,293 | $10.30 | $3,422,617.90 |
DisclosureSEC source: 0000899243-20-030857 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 60,632,356 F1 · kind: On November 9, 2020, BC Perception Holdings, LP ("BC Perception") purchased 332,293 shares of the Issuer's Common Stock at a price of $10.30 per share. F2 · ownership.nature: Christopher Gordon is a Managing Director of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the managing directors of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 20:00 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 10,000,000 | $10.00 | $100,000,000.00 |
DisclosureSEC source: 0000899243-20-029741 · doc4.xml · nonDerivative · entry 2 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 60,300,063 F2 · kind: On October 27, 2020, BC Perception purchased 10,000,000 shares of the Issuer's Common Stock from the Issuer at a price of $10.00 per share. F3 · ownership.nature: Christopher Gordon is a Managing Director of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the managing directors of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 20:00 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | OtherCommon Stock | 49,961,943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029741 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 50,300,063 F1 · kind: On October 27, 2020, Cerevel Therapeutics Holdings, Inc. (f/k/a ARYA Sciences Acquisition Corp II, the "Issuer") consummated a business combination (the "Business Combination") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. ("Cerevel"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, BC Perception Holdings, LP ("BC Perception") received 49,961,943 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by BC Perception prior to the Business Combination. F1 · price: On October 27, 2020, Cerevel Therapeutics Holdings, Inc. (f/k/a ARYA Sciences Acquisition Corp II, the "Issuer") consummated a business combination (the "Business Combination") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. ("Cerevel"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, BC Perception Holdings, LP ("BC Perception") received 49,961,943 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by BC Perception prior to the Business Combination. F3 · ownership.nature: Christopher Gordon is a Managing Director of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the managing directors of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 03, 2018 Filed May 7, 2018 16:18 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | GrantCommon Stock | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011637 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,328 F1 · shares: Shares will vest over a 3-year period in equal annual installments beginning May 3, 2019. Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 17:44 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | SaleCommon Stock, par value $0.01 | 998,438 | $50.69 | $50,610,822.22 |
DisclosureSEC source: 0000899243-17-020976 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · ownership.nature: Represents shares of Common Stock held directly by Bain Capital Fund VIII, LLC, Bain Capital VIII Coinvestment Fund, LLC, Bain Capital (CR), L.P., BCIP Associates III, LLC, BCIP Associates III-B, LLC, BCIP T Associates III, LLC, BCIP T Associates III-B, LLC, and BCIP Associates-G (collectively, the "Bain Capital Entities"). F2 · ownership.nature: The governance, investment strategy and decision-making process with respect to investments held by the Bain Capital Entities is directed by the Global Private Equity Board of Bain Capital Investors, LLC ("BCI"). Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 16:06 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | SaleCommon Stock, par value $0.01 | 2,453,764 | $51.65 | $126,736,910.60 |
DisclosureSEC source: 0000899243-17-019535 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 998,438 F1 · ownership.nature: Represents shares of Common Stock held directly by Bain Capital Fund VIII, LLC, Bain Capital VIII Coinvestment Fund, LLC, Bain Capital (CR), L.P., BCIP Associates III, LLC, BCIP Associates III-B, LLC, BCIP T Associates III, LLC, BCIP T Associates III-B, LLC, and BCIP Associates-G (collectively, the "Bain Capital Entities"). F2 · ownership.nature: The governance, investment strategy and decision-making process with respect to investments held by the Bain Capital Entities is directed by the Global Private Equity Board of Bain Capital Investors, LLC ("BCI"). Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Capital Entities. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:23 UTC | Acadia Healthcare Company, Inc. ACHC · Entity 4312 | GrantCommon Stock, par value $0.01 | 3,752 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-014549 · doc4.xml · nonDerivative · entry 1 Gordon Christopher R · CIK 0001432313 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,203 F1 · shares: Shares will vest over a 3-year period in equal annual installments beginning May 25, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.